Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Current Assets (2017 - 2025)

Cue Biopharma (CUE) has disclosed Current Assets for 9 consecutive years, with $37.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 47.12% to $37.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.0 million through Dec 2025, up 47.12% year-over-year, with the annual reading at $37.0 million for FY2025, 47.12% up from the prior year.
  • Current Assets hit $37.0 million in Q4 2025 for Cue Biopharma, up from $25.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $79.7 million in Q2 2021 to a low of $15.9 million in Q1 2025.
  • Historically, Current Assets has averaged $53.4 million across 5 years, with a median of $59.2 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 51.21% in 2021 and later tumbled 64.34% in 2025.
  • Year by year, Current Assets stood at $68.5 million in 2021, then increased by 12.73% to $77.2 million in 2022, then tumbled by 33.34% to $51.5 million in 2023, then tumbled by 51.14% to $25.1 million in 2024, then surged by 47.12% to $37.0 million in 2025.
  • Business Quant data shows Current Assets for CUE at $37.0 million in Q4 2025, $25.8 million in Q3 2025, and $30.8 million in Q2 2025.